Pioneering biogenerics
Learn more about our state-of-the-art biosimilar facility
Explore
Company
Who we are
Alvotech is a privately owned biopharmaceutical company focused on the development and manufacturing of high quality biosimilars for global markets. We are specialists in biotechnology all working towards a common goal ...
Research and development
WHAT WE DO
Our vision as a company is to build a leading global biopharmaceutical company, while focusing on the development, and the commercialization of medicines for the treatment of severe, immune, inflammatory conditions.
Newsroom
Alvotech enrolls first patient in clinical phase III study
Alvotech enrolls first patient in clinical phase III study involving biosimilar version of HUMIRA®
- Alvotech’s AVT02 is being developed as a biosimilar of the HUMIRA® high-concentration (100mg/mL) product, expected to be more convenient for patients, compared to biosimilar competitors
Meet management
World Class team
Our organizational structure is effective, flexible and has a proven track record that will enable the company to bring new biopharmaceutical products quickly and safely to market. The leadership team is helmed by Rasmus Rojkjaer.
Partnerships
Partnering with Alvotech is gaining access to high quality, ready to market biosimilars